Krassen Nedeltchev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Krassen Nedeltchev has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Heinrich Paul Mattle
Department of Neurology, Inselspital, University of Bern, Bern, Switzerland
4 shared publications - Marcel Arnold
Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland
2 shared publications Alberto Cremonesi
Gruppo Villa Maria Endovascular, Villa Maria Cecilia Hospital, Cotignola, Italy
1 shared publicationAlexander Schnabel
1 shared publicationAly Talen
Genae associates nv, Antwerp, Belgium
1 shared publicationAmir Khan
1 shared publication
Latest Publications
- 18 June 2018
- Published by Cambridge University Press (CUP)
- p. 245-249
Cerebrovascular Manifestations of Neurofibromatosis
- 18 June 2018
- Published by Cambridge University Press (CUP)
- p. 245-249
Cerebrovascular Manifestations of Neurofibromatosis
- 1 March 2012
- Published by Wolters Kluwer Health in Stroke
- Vol. 43 (3) , 922-923
Critique of Apixaban Versus Warfarin in Patients With Atrial Fibrillation
- 1 March 2012
- Published by Wolters Kluwer Health in Stroke
- Vol. 43 (3) , 922-923
Critique of Apixaban Versus Warfarin in Patients With Atrial Fibrillation
- 24 August 2010
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 76 (3) , 333-344
Standardized definitions and clinical endpoints in carotid artery and supra‐aortic trunk revascularization trials
Background: Endovascular therapy has emerged as a promising alternative to open surgery for stroke prevention in patients with obstructive disease of the supra‐aortic arteries. Although most previous studies have used similar safety and efficacy endpoints, differences in definitions, timing of assessments, and standards of reporting have hampered direct comparisons across various trials. Methods and results: The DEFINE group, an informal collaboration of multidisciplinary physicians, involved in the therapy of patients with obstructive disease of the supra‐aortic arteries in Europe and the United States reviewed the current literature and, after extensive correspondence and meetings, proposed the definitions outlined in the present manuscript. Three meetings including all authors of the manuscript, along with representatives of the United States Food and Drug Administration (FDA) and commercial device manufacturers were held in Barcelona, Spain, in May 2008, in Munich, Germany, in July 2008, and in New York in November 2008. The proposed definitions encompass baseline clinical and anatomic characteristics, clinical and radiologic outcomes, complications, standards of reporting, and timing of assessment. Conclusions: Considering the broad consensus between the multidisciplinary scientific members and the regulatory authorities, the proposed definitions are expected to find adoption in future clinical investigations. These definitions can be applied to both endovascular and open surgery trials and will allow reliable comparisons between these two revascularization methods.
- 24 August 2010
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 76 (3) , 333-344
Standardized definitions and clinical endpoints in carotid artery and supra‐aortic trunk revascularization trials
Background: Endovascular therapy has emerged as a promising alternative to open surgery for stroke prevention in patients with obstructive disease of the supra‐aortic arteries. Although most previous studies have used similar safety and efficacy endpoints, differences in definitions, timing of assessments, and standards of reporting have hampered direct comparisons across various trials. Methods and results: The DEFINE group, an informal collaboration of multidisciplinary physicians, involved in the therapy of patients with obstructive disease of the supra‐aortic arteries in Europe and the United States reviewed the current literature and, after extensive correspondence and meetings, proposed the definitions outlined in the present manuscript. Three meetings including all authors of the manuscript, along with representatives of the United States Food and Drug Administration (FDA) and commercial device manufacturers were held in Barcelona, Spain, in May 2008, in Munich, Germany, in July 2008, and in New York in November 2008. The proposed definitions encompass baseline clinical and anatomic characteristics, clinical and radiologic outcomes, complications, standards of reporting, and timing of assessment. Conclusions: Considering the broad consensus between the multidisciplinary scientific members and the regulatory authorities, the proposed definitions are expected to find adoption in future clinical investigations. These definitions can be applied to both endovascular and open surgery trials and will allow reliable comparisons between these two revascularization methods.
- Open Access
- 1 November 2009
- Published by Wolters Kluwer Health in Stroke
- Vol. 40 (11)
Response to Letter by Metso et al
- 1 November 2009
- Published by Wolters Kluwer Health in Stroke
- Vol. 40 (11)
Open AccessResponse to Letter by Metso et al
- 9 October 2008
- Published by Cambridge University Press (CUP)
- p. 221-224
CEREBROVASCULAR MANIFESTATIONS OF NEUROFIBROMATOSIS
This chapter contains detailed, up-to-date information about the nature, diagnosis, and treatment of Ehlers-Danlos syndromes (EDS) that cause strokes. The EDS are a group of connective tissue diseases classically characterized by fragile or hyperelastic skin, hyperextensible joints, vascular lesions, and easy bruising and excessive scarring after an injury. Numerous mutations of the COL3A1 gene on chromosome 2, including point mutations, exon skipping mutations, and multi-exon deletions, have been attributed to this disease. EDS patients develop arterial dissections. The cerebrovascular complications include intracranial aneurysms, arterial rupture, carotid-cavernous fistulae, and arterial dissections. The intracranial internal carotid artery is the most common site for an aneurysm, and rupture of the internal carotid artery within the cavernous sinus can create a direct carotid-cavernous fistula. The fragile arteries make angiography and surgery difficult, but some patients have had successful surgery or endovascular treatment.
- 9 October 2008
- Published by Cambridge University Press (CUP)
- p. 221-224
CEREBROVASCULAR MANIFESTATIONS OF NEUROFIBROMATOSIS
This chapter contains detailed, up-to-date information about the nature, diagnosis, and treatment of Ehlers-Danlos syndromes (EDS) that cause strokes. The EDS are a group of connective tissue diseases classically characterized by fragile or hyperelastic skin, hyperextensible joints, vascular lesions, and easy bruising and excessive scarring after an injury. Numerous mutations of the COL3A1 gene on chromosome 2, including point mutations, exon skipping mutations, and multi-exon deletions, have been attributed to this disease. EDS patients develop arterial dissections. The cerebrovascular complications include intracranial aneurysms, arterial rupture, carotid-cavernous fistulae, and arterial dissections. The intracranial internal carotid artery is the most common site for an aneurysm, and rupture of the internal carotid artery within the cavernous sinus can create a direct carotid-cavernous fistula. The fragile arteries make angiography and surgery difficult, but some patients have had successful surgery or endovascular treatment.
- 4 October 2008
- Vol. 138, 567-72
Safety and feasibility of percutaneous closure of patent foramen ovale without intra-procedural echocardiography in 825 patients.
Percutaneous closure of patent foramen ovale (PFO) is generally performed using intra-procedural guidance by transoesophageal (TEE) or intracardiac (ICE) echocardiography. While TEE requires sedation or general anaesthesia, ICE is costly and adds incremental risk, and both imaging modalities lengthen the procedure. A total of 825 consecutive patients (age 51 +/- 13 years; 58% male) underwent percutaneous PFO closure solely under fluoroscopic guidance, without intra-procedural echocardiography. The indications for PFO closure were presumed paradoxical embolism in 698 patients (95% cerebral, 5% other locations), an embolic event with concurrent aetiologies in 47, diving in 51, migraine headaches in 13, and other reasons in 16. An atrial septal aneurysm was associated with the PFO in 242 patients (29%). Permanent device implantation failed in two patients (0.2%). There were 18 procedural complications (2.2%), including embolization of the device or parts of it in five patients with successful percutaneous removal in all cases, air embolism with transient symptoms in four patients, pericardial tamponade requiring pericardiocentesis in one patient, a transient ischaemic attack with visual symptoms in one patient, and vascular access site problems in seven patients. There were no long-term sequelae. Contrast TEE at six months showed complete abolition of right-to-left shunt via PFO in 88% of patients, whereas a minimal, moderate or large residual shunt persisted in 7%, 3%, and 2%, respectively. This study confirms the safety and feasibility of percutaneous PFO closure without intra-procedural echocardiographic guidance in a large cohort of consecutive patients.
- 4 October 2008
- Vol. 138, 567-72
Safety and feasibility of percutaneous closure of patent foramen ovale without intra-procedural echocardiography in 825 patients.
Percutaneous closure of patent foramen ovale (PFO) is generally performed using intra-procedural guidance by transoesophageal (TEE) or intracardiac (ICE) echocardiography. While TEE requires sedation or general anaesthesia, ICE is costly and adds incremental risk, and both imaging modalities lengthen the procedure. A total of 825 consecutive patients (age 51 +/- 13 years; 58% male) underwent percutaneous PFO closure solely under fluoroscopic guidance, without intra-procedural echocardiography. The indications for PFO closure were presumed paradoxical embolism in 698 patients (95% cerebral, 5% other locations), an embolic event with concurrent aetiologies in 47, diving in 51, migraine headaches in 13, and other reasons in 16. An atrial septal aneurysm was associated with the PFO in 242 patients (29%). Permanent device implantation failed in two patients (0.2%). There were 18 procedural complications (2.2%), including embolization of the device or parts of it in five patients with successful percutaneous removal in all cases, air embolism with transient symptoms in four patients, pericardial tamponade requiring pericardiocentesis in one patient, a transient ischaemic attack with visual symptoms in one patient, and vascular access site problems in seven patients. There were no long-term sequelae. Contrast TEE at six months showed complete abolition of right-to-left shunt via PFO in 88% of patients, whereas a minimal, moderate or large residual shunt persisted in 7%, 3%, and 2%, respectively. This study confirms the safety and feasibility of percutaneous PFO closure without intra-procedural echocardiographic guidance in a large cohort of consecutive patients.
- 1 May 2004
- Published by Wolters Kluwer Health in Stroke
- Vol. 35 (5) , 1135-1138
Outcome of Acute Stroke Patients Without Visible Occlusion on Early Arteriography
Background— The aim of this study was to determine the clinical and radiological outcome of acute stroke patients who had no vessel occlusion on arteriography and to define predictors of clinical outcome. Methods— We analyzed clinical and radiological data of stroke patients whose arteriography performed within 6 hours of symptom onset did not visualize any vessel occlusion. Results— Twenty-eight of 283 consecutive patients (10%) who underwent arteriography with the intention to perform intraarterial thrombolysis did not show any arterial occlusion. Their median baseline National Institutes of Health Stroke Scale (NIHSS) score was 7. Time from symptom onset to arteriography ranged from 115 to 315 minutes; on average, it was 226 minutes. Presumed stroke cause was cardiac embolism in 11 patients (39%), small artery disease in 6 (21%), coronary angiography in 1 (4%), and undetermined in 10 patients (36%). After 3 months, modified Rankin Scale score (mRS) was ≤2 in 21 patients (75%), indicating a favorable outcome. Six patients (21%) had a poor outcome (mRS 3 or 4) and 1 patient (4%) had a myocardial infarction and died. Twenty-seven patients had follow-up brain imaging. It was normal in 5, showed a lacunar lesion in 8, a striatocapsular infarct in 2, a small or medium-sized anterior circulation infarct in 6, multiple small anterior circulation infarcts in 2, and multiple posterior circulation infarcts in 4. No predictors of clinical outcome were identified. Conclusions— Most acute stroke patients with normal early arteriography show infarcts on brain imaging; however, clinical outcome is usually favorable.
- 1 May 2004
- Published by Wolters Kluwer Health in Stroke
- Vol. 35 (5) , 1135-1138
Outcome of Acute Stroke Patients Without Visible Occlusion on Early Arteriography
Background— The aim of this study was to determine the clinical and radiological outcome of acute stroke patients who had no vessel occlusion on arteriography and to define predictors of clinical outcome. Methods— We analyzed clinical and radiological data of stroke patients whose arteriography performed within 6 hours of symptom onset did not visualize any vessel occlusion. Results— Twenty-eight of 283 consecutive patients (10%) who underwent arteriography with the intention to perform intraarterial thrombolysis did not show any arterial occlusion. Their median baseline National Institutes of Health Stroke Scale (NIHSS) score was 7. Time from symptom onset to arteriography ranged from 115 to 315 minutes; on average, it was 226 minutes. Presumed stroke cause was cardiac embolism in 11 patients (39%), small artery disease in 6 (21%), coronary angiography in 1 (4%), and undetermined in 10 patients (36%). After 3 months, modified Rankin Scale score (mRS) was ≤2 in 21 patients (75%), indicating a favorable outcome. Six patients (21%) had a poor outcome (mRS 3 or 4) and 1 patient (4%) had a myocardial infarction and died. Twenty-seven patients had follow-up brain imaging. It was normal in 5, showed a lacunar lesion in 8, a striatocapsular infarct in 2, a small or medium-sized anterior circulation infarct in 6, multiple small anterior circulation infarcts in 2, and multiple posterior circulation infarcts in 4. No predictors of clinical outcome were identified. Conclusions— Most acute stroke patients with normal early arteriography show infarcts on brain imaging; however, clinical outcome is usually favorable.